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Abstract
Background—The Institute of Medicine suggests that consistent survivorship care plan (SCP) 
use involves developing and delivering SCPs to all cancer survivors and their primary care 
providers (PCPs). We describe the consistency of SCP use in US cancer programs and assess its 
relationship with cancer program-level determinants.
Methods—We surveyed employees knowledgeable about survivorship practices in cancer 
programs reporting current SCP use (n=36; 81% response rate). We operationalized consistent 
SCP use as whether SCPs were (1) developed for ≥75% survivors; (2) delivered to ≥75% 
survivors; (3) delivered to ≥75% PCPs; and (4) all of the above. We use descriptive statistics to 
report SCP use consistency and evaluate associations using Fisher’s Exact and Wilcoxon Rank 
Sum tests.
Results—SCPs were developed for ≥75% survivors in five programs (15%); eight (25%) 
delivered ≥75% SCPs to survivors; seven (23%) delivered ≥75% SCPs to PCPs; only one program 
(4%) met all three criteria. We found relationships between SCP use consistency and geographic 
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region (p = .05); initiating SCP use in response to survivors’ requests (p = .03); and membership in 
the National Cancer Institute’s National Community Cancer Centers Program (p = .01).
Conclusion—SCP use is highly inconsistent. Survivors and cancer care quality improvement 
organizations may play a key role in improving the consistency of SCP use in US cancer 
programs. Survivors can initiate SCP use. Cancer care quality improvement organizations can 
specify how cancer programs’ compliance with SCP guidelines will be assessed. Future research 
should identify mechanisms underlying the relationships that we found.
Keywords
Survivorship care plan; health care quality; barriers; cancer program
Introduction
The transition from cancer treatment to follow-up care is often difficult for the nearly 14 
million cancer survivors in the United States [27]. Survivors have unique physical, 
psychological, social, and spiritual health needs that are optimally addressed through the 
prevention and detection of new cancers, surveillance for cancer spread or recurrence, 
intervention for consequences of cancer and its treatment, and coordination between 
oncologists and primary care providers (PCPs) [16, 7, 29]. Optimal care may be 
compromised by PCPs’ and oncologists’ conflicting perspectives on their roles in 
survivorship care, which may result in the duplication or omission of services [5, 10, 24]. 
Survivors often report feeling poorly educated regarding psychological, social, and sexual 
health issues and their risk for recurrence, and they report being dissatisfied with care 
following cancer treatment [15, 1, 21, 18].
Citing the unmet needs of US cancer survivors, the Institute of Medicine (IOM) report From 
Cancer Patient to Cancer Survivor: Lost in Translation recommended survivorship care 
plans (SCPs) as tools for improving communication among oncologists, survivors, and PCPs 
[16]. SCPs are written documents that often, but not always, include a summary of cancer 
treatment and recommendations for surveillance, preventive care, wellness behaviors, and 
symptoms to report following treatment. The IOM report suggested that high-quality SCP 
use involves including in SCPs each element of the IOM’s framework (e.g., likely course of 
recovery). The report suggested that consistent SCP use involves developing and delivering 
SCPs to all survivors and their PCPs.
Evidence suggests that few cancer programs meet the IOM’s recommendations for high-
quality SCP use [28, 26]; the extent to which cancer programs meet the IOM’s 
recommendations for consistent SCP use is less clear. In a previous study, we found a 
discrepancy between SCPs development and delivery to survivors and PCPs across US 
cancer programs [4]. The extent to which SCPs are developed but not delivered within 
cancer programs is unknown. If SCPs are not developed and delivered to all survivors and 
their PCPs – that is, used consistently – then the intent underlying the IOM’s 
recommendation to use SCPs as a tool to foster communication among survivors, 
oncologists, and PCPs will not be met, regardless of content.
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In this paper, we (1) describe SCP use consistency in US cancer programs and (2) assess 
relationships between SCP use consistency and hypothesized determinants (e.g., cancer 
program characteristics). In so doing, we fill a gap in the literature and describe current 
levels of compliance with SCP use guidelines. Results also encourage cancer care quality 
improvement organizations to consider how to assess compliance with guidelines. 
Specifically, is developing high-quality SCPs sufficient to comply with guidelines, or is 
delivering SCPs to survivors and their PCPs also necessary for compliance? This clarity and 




We conducted a cross-sectional survey of cancer programs throughout the US with a wide 
range of annual incident cancers, program types, and cancer care quality improvement 
organization (e.g., Commission on Cancer [CoC]) memberships. A sampling frame was 
created for programs with membership in at least one of the following cancer care quality 
improvement organizations: CoC [8], the Association of Community Cancer Centers [3], the 
National Comprehensive Cancer Network [20], and/or the American Society of Clinical 
Oncology’s Quality Oncology Practice Initiative [2]. We took this approach because CoC 
programs serve 80 percent of all newly diagnosed US cancer patients [8]; therefore, our 
sampling frame included programs that serve the majority of US cancer survivors. We 
improved upon these figures by including programs that were members of cancer care 
quality improvement organizations other than CoC.
After eliminating programs with the same name in the same state, 1,991 programs were 
included in the sampling frame. We eliminated another 141 programs that were duplicate 
listings of programs with different names but the same location and/or staff. The final 
sampling frame included a total of 1,850 programs. Given the time-consuming process of 
identifying potential survey respondents (employees with knowledge regarding survivorship 
practices; see below) from these 1,850 programs, we drew a simple random sample of 100 
programs (5%).
Survey development
The survey was based on a review of the Institute of Medicine’s report: From Cancer Patient 
to Cancer Survivor: Lost in Transition [16] and scientific literature. A team of experts 
developed the survey. Survivorship experts, including a practicing provider of breast cancer 
survivorship care, ensured that the survey reflected relevant clinical and policy issues, such 
as the importance of developing and delivering SCPs to survivors and their PCPs, and 
activities of key cancer care quality improvement organizations. Experts in dissemination 
and implementation of innovations in cancer care ensured that the survey reflected key 
indicators of SCP use consistency. Survey methodologists promoted the likelihood that 
potential respondents would complete the survey. We also refined the survey based on 
cognitive interviews with 8 employees who had knowledge of survivorship practices in 
programs not included in the final study sample. Survey items were phrased to elicit 
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responses regarding SCP use any time in their program’s history. The final survey consisted 
of 15 items (see Table 1).
Survey respondent identification
We acknowledge that SCP use consistency may vary within cancer programs. However, 
given our objective of identifying organization-level determinants of SCP use consistency, 
we sought a single respondent per program who could answer questions about their 
program’s characteristics (e.g., annual incident cancers). The following method was used to 
identify potential respondents. A research assistant used publicly available information to 
call sampled programs to identify employees with knowledge regarding survivorship 
practices who could respond to the survey. The research assistant asked for someone in the 
program who knew about how the program’s survivors were transitioned to follow-up care 
after treatment was complete. This process continued until the research assistant identified 
an employee in the program who would be able to answer questions regarding (1) whether 
or not SCPs were used in the program and (2) reasons why SCPs were or were not used in 
the program. The research assistant collected a specific address, direct phone number, and 
email address for the employee.
Survey administration
The survey was conducted between January and May 2013 using the standards of Dillman’s 
Total Design Method [9]. Initially, depending on the availability of an email address, we 
sent an email or a letter to respondents letting them know that they would soon receive an 
invitation to complete the survey. Three days later, we sent an introductory email with a link 
to an online version of the survey or an envelope containing a cover letter, survey, and 
return envelope. Emails or postcards were sent to thank respondents who completed the 
survey and to remind non-respondents to complete the survey. Two weeks after the initial 
survey mailing, replacement surveys were sent to non-respondents by first class mail or 
email. Two weeks later, non-respondents were called to request a response. This pattern 
repeated, allowing two-week intervals between contacts for as many as ten total attempts. 
Upon completing the survey, respondents had the option of being entered into a raffle to win 
an iPad. An employee with knowledge of survivorship practices from 81 of the 100 
programs contacted completed the survey (81% response rate). The sample for the study 
reported here includes cancer programs in which respondents reported that SCPs were used 
at the time of the survey (“regularly” or “sometimes”; n = 36). The other 45 respondents 
reported that SCPs were not used in their cancer programs at the time of the survey, so they 
were excluded from the present study. The institutional review board at the University of 
North Carolina at Chapel Hill exempted the study from human subjects review.
Variable descriptions
Survey items and response options are listed in Table 1. To measure SCP use consistency, 
we asked respondents, to the best of their ability, to estimate the percentage of survivors for 
whom SCPs were developed and the percentages of survivors and PCPs to whom SCPs were 
delivered. We operationalized consistent SCP use in four ways: SCPs were (1) developed 
for at least 75 percent of the cancer program’s survivors; (2) delivered to at least 75 percent 
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of survivors for whom an SCP was developed; (3) delivered to at least 75 percent of 
survivors’ PCPs; and (4) all three of the above (see Table 2).
Determinants of SCP use consistency—Cancer programs may be more likely to use 
SCPs consistently when the motivation, means, and opportunity exist [30]. To assess 
motivation to use SCPs consistently, we asked respondents why SCPs were used in their 
programs (e.g., survivors requested SCPs). To assess whether or not cancer programs had 
the means to use SCPs consistently, we asked respondents about barriers to SCP use in their 
program. We operationalized the opportunity to use SCPs consistently as cancer program 
characteristics that might increase their chances of consistently using SCPs. For example, 
studies have shown relationships between health services utilization and geographic location 
[23, 12, 31, 13]. To assess geographic variation in SCP use consistency, we captured 
programs’ location using ZIP codes. When available, ZIP codes were converted to rural/
urban indicators using Rural-Urban Commuting Areas data [25]. ZIP codes were identified 
as a rural or urban subtype; subtypes were aggregated into dichotomous rural and urban 
categories. To assess variation in SCP use consistency across program size, we 
operationalized annual incident cancers as a program’s unduplicated number of cancer 
patients. American College of Surgeons assigns the program types listed in Table 1 based on 
organization type (e.g., academic), services provided, and number of cancer patients served 
[2]. To assess variation in SCP use consistency associated with cancer care quality 
improvement organizations’ SCP use guidelines and recommendations, we asked 
respondents whether their program was a member of one of the organizations listed in Table 
1. Since program members’ professional background may influence their perspective on 
SCP use, respondents were also asked which position they held at their program at the time 
of the survey.
Analysis
The unit of analysis was the program. To describe SCP use consistency and program and 
respondent characteristics, we report response frequencies and percentages with 95% exact 
binomial confidence limits around select percentages. To compare (1) respondents to 
programs in the sampling frame not randomly selected for inclusion in the study sample and 
(2) programs that consistently used SCPs to those that did not consistently use SCPs, we 
used Wilcoxon Rank Sum tests for continuous independent variables (e.g., annual incident 
cancers) and Fisher’s exact tests for categorical independent variables (e.g., program type). 
Unadjusted two-tailed p-values are reported. Relationships between variables were 
considered significant at the p < .05 level. Analyses were conducted using SAS statistical 
software v9.3 (Cary, NC).
Results
There were no differences in location, annual incident cancers, or program type between 
programs that returned surveys and programs that were not included in the sample (all p > .
13).
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SCP use consistency—The majority of respondents (25/36; 69%; CI: 52–84%) 
indicated that SCPs were used for fewer than half of survivors in their programs. In most 
programs, SCPs rarely reached their intended audience: Most respondents reported that 
SCPs were delivered to 50% or fewer survivors (22/35; 63%; CI: 45–97%) or their PCPs 
(22/36; 61%; CI: 43–77%).
Table 2 contains descriptive statistics for variables representing SCP use consistency. 
Respondents did not always know the answers to the survey questions, so not all programs 
could be classified. Few cancer programs consistently used SCPs: Fifteen percent of 
respondents (5/33; CI: 5–32%) reported that SCPs were developed for at least 75 percent of 
the cancer program’s survivors; a quarter (8/32; CI: 11–43%) delivered at least 75 percent of 
SCPs to survivors for whom an SCP was developed; a quarter (7/30; CI: 10–42%) delivered 
at least 75 percent of SCPs to survivors’ PCPs; and only one program of 26 (4%; CI: 1–
20%) developed and delivered SCPs to at least 75 percent of survivors and their PCPs.
Hypothesized determinants of SCP use consistency—Barriers to SCP use. The 
most commonly reported barrier to SCP use was lack of resources (80%). Other commonly 
cited barriers included the perception that SCPs are difficult to use (29%), that influential 
people (e.g., physician champions, managers) had not advocated for SCPs to be used (26%), 
and the perception that SCPs are not useful (20%). Few respondents cited other barriers, 
such as the perception that influential people’s advocacy does not motivate providers to use 
SCPs (9%), that providers do not feel confident in using SCPs (6%), or lack of opportunities 
to use SCPs (3%).
Reasons for SCP use. The most commonly cited reason for using SCPs was the CoC’s 2012 
program standards (75%). Other commonly cited reasons were the belief that SCP use may 
improve quality of care (69%), National Comprehensive Cancer Network guidelines (47%), 
American Society for Clinical Oncology guidelines (39%), and the National Cancer 
Institute’s National Community Cancer Centers Program (NCCCP) guidelines (39%).
Cancer program characteristics. Two respondents were physicians (6%), 8 were nurse 
practitioners (23%), 14 were registered nurses (40%), 6 were other clinical staff (17%), and 
5 were non-clinical administrative staff (14%). Respondents reported an average of 1,280 
annual incident cancers (range 1–14,000) in their programs. A third of respondents were 
employed in community comprehensive cancer programs (29%), a quarter (24%) came from 
academic cancer programs, a fifth were employed in community hospital cancer programs 
(20%), and less than 10 percent of sampled programs fell into other program type categories, 
including National Cancer Institute comprehensive cancer programs and pediatric cancer 
programs. Most respondents’ programs were members of CoC (83%). Forty-three percent of 
respondents were members of the Association of Community Cancer Centers. A third of 
respondents were members of the American Society of Clinical Oncology’s Quality 
Oncology Practice Initiative (34%) and National Comprehensive Cancer Network (33%). A 
quarter of respondents’ programs were members of the National Comprehensive Cancer 
Control Program (23%). Most cancer programs were located in the Midwestern US (38%); 
nearly a third (29%) were in the South; eighteen percent were in the West; and fifteen 
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percent were in the Northeast. Ninety-one percent were in urban locations; nine percent 
were rural.
Relationships between SCP use consistency and hypothesized determinants
SCPs developed for at least 75 percent of the cancer program’s survivors—
Differences among regions were detected with respect to whether or not SCPs were 
developed for at least 75 percent of cancer programs’ survivors (p = .05). In particular, 
cancer programs in the Northeast delivered SCPs for at least 75 percent of their survivors 40 
percent (2/5) of the time, whereas cancer programs in the West, Midwest and South reported 
doing so infrequently (0 percent [0/5], 0 percent [0/12], and 20 percent [2/10], respectively). 
Other hypothesized relationships were not statistically significant.
SCPs delivered to at least 75 percent of survivors—We found no statistically 
significant relationships between hypothesized determinants and whether or not SCPs were 
delivered to at least 75 percent of survivors for whom an SCP was developed.
SCPs delivered to at least 75 percent of survivors’ PCPs—Regional differences 
were detected with respect to whether or not SCPs were delivered to at least 75 percent of 
survivors’ PCPs (p = .02). In particular, cancer programs in the Northeast delivered SCPs to 
at least 75 percent of survivors’ PCPs 80 percent of the time (4/5), whereas cancer programs 
in the West, Midwest and South did so infrequently (17 percent [1/6], 10 percent [1/10], and 
11 percent [1/9], respectively). Using SCPs per survivors’ request was positively associated 
with delivering SCPs to at least 75 percent of survivors’ PCPs (p = .03): Seventy-five 
percent (3/4) of programs that began using SCPs per survivors requests delivered them to 
survivors’ PCPs 75 percent of the time, compared to only 15 percent (4/26) of those that 
began for other reasons. Other hypothesized relationships were not statistically significant.
SCPs developed for at least 75 percent of the cancer program’s survivors and 
delivered to at least 75 percent of survivors and their PCPs—Only one program 
indicated that SCPs were developed and delivered to both survivors and their PCPs at least 
75 percent of the time. As such, associations were not assessed for this indicator of SCP use 
consistency.
SCPs delivered to at least 75 percent of survivors and their PCPs—In post-hoc 
analysis, we assessed another measure of SCP use consistency: whether SCPs were 
delivered to at least 75 percent of survivors and their PCPs (this measure eliminated the 
requirement that SCPs be developed for at least 75 percent of the cancer program’s 
survivors). Five respondents’ cancer programs (14 percent [5/28]) met this definition of SCP 
use consistency. We found that members of NCCCP were more likely to deliver SCPs to 
both survivors and their PCPs compared to those that were not members (50 percent [4/8] 
versus 5 percent [1/20]; p = .01).
Discussion
The IOM suggested that consistent SCP use involves developing and delivering SCP to all 
survivors and their PCPs [16]. Evidence of the extent to which SCPs are used consistently is 
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scant. In this paper, our objectives were to (1) describe SCP use consistency in US cancer 
programs and (2) assess relationships between SCP use consistency and hypothesized 
determinants. Our results suggest that SCP use is highly inconsistent in US cancer programs. 
Few cancer programs develop SCPs for all survivors, let alone deliver SCPs to all survivors 
and their PCPs. In fact, we found that only one cancer program used SCPs according to IOM 
recommendations, developing and delivering SCPs to all survivors and their PCPs. We 
describe several possible explanations for the gap that we found between SCP development 
and delivery elsewhere [4]. Briefly, cancer programs may not have fully implemented SCPs 
at the time of the survey – nearly two years before SCP use requirements take effect; 
programs may lack the resources to deliver SCPs; or they may develop SCPs to meet 
minimum standards for compliance with cancer care quality improvement organizations’ 
SCP use requirements.
Interestingly, our results suggest that SCPs reach PCPs almost as often as they reach 
survivors. This is surprising, given that delivering SCPs to PCPs requires an additional step 
for cancer programs or survivors. Our finding that SCPs were more frequently delivered to 
PCPs in cancer programs that began using SCPs per survivors’ request may offer clarity: 
Survivors who request SCPs may be motivated to ensure that their PCPs receive a copy. Our 
cross-sectional study design limits our ability to infer causality, so reverse causality is 
possible: Survivors who were more likely to request SCPs may have chosen cancer 
programs that offer SCPs; however, survey item wording minimizes this possibility (see 
Table 1). Consistent SCP use was also positively associated with NCCCP membership; 
NCCCP’s SCP use goals and support may facilitate SCP use.
We also found regional variation in SCP use consistency. The patterns that we detected are 
aligned with studies that have found geographic variation in the use of other health services 
[23, 12, 31, 13]. In particular, SCPs are more consistently used in the Northeastern US. 
Scholars have suggested that variation may be attributed to regional variation in 
sociodemographics and payment structures. The extent to which these factors apply to SCP 
use consistency is unclear. Evidence of disparities in the receipt of SCPs across 
sociodemographic factors including survivor age and gender exists [17], but it is unclear 
whether disparities exist across regions. Anecdotal evidence suggests that some cancer 
programs have identified mechanisms for reimbursement for activities related to SCP use, 
but whether geographic variation in reimbursement opportunities exists is unclear.
Limitations
Our study has several limitations. Survey items were not validated. Consequently, 
respondents may have varied in how they interpreted the items about SCP development and 
delivery despite our effort to word survey items to emphasize the distinction between SCP 
development and delivery (see Table 1). Measurement bias may have contributed to our 
nonsensical finding that there were more respondents who reported delivering an SCP to at 
least 75 percent of survivors and their PCPs than respondents who reported developing and 
delivering an SCP to at least 75 percent of survivors and their PCPs; ostensibly, an SCP 
must be developed prior to delivery. Further, we did not ask respondents to distinguish 
between reasons and barriers to SCP development and SCP delivery. This limits our ability 
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to assess relationships between SCP use consistency and hypothesized determinants. 
Measurement bias emphasizes the need for the development of measures in dissemination 
and implementation research [11]. Validated measures will promote stronger research in a 
rapidly developing field. In addition, social desirability bias may have caused respondents to 
over-report SCP use.
Our sampling frame may not have been accurate. Using cancer care quality improvement 
organizations’ websites to develop the sampling frame may have resulted in duplicates, 
despite our efforts to eliminate them. Also, our sampling frame excluded programs that are 
not members of at least one cancer care quality improvement organization; however, our 
sampling frame included all CoC programs, which serve 80% of all newly diagnosed US 
cancer patients [8].
Our sample size limited our ability to detect small but potentially meaningful relationships 
between SCP use consistency and hypothesized determinants. We were unable to conduct 
some analyses because, for example, only one cancer program reported that SCPs were 
developed and delivered to at least 75 percent of survivors and their PCPs. Future studies 
may be able to assess these relationships because SCP use will likely increase when CoC 
SCP use program standards go into effect in 2015.
Implications
Despite the limitations described above, our findings have implications for cancer care 
quality improvement organizations, cancer programs, providers, and survivors. Amidst 
pervasive evidence of poor communication between oncologists and PCPs [6, 24], recent 
scholarship emphasizes the need to ensure SCPs’ practical and clinical benefits [22]. 
However, the focus on studying SCPs’ effectiveness may be premature until SCPs are more 
routinely used. In light of the inconsistent SCP use we found in this study, SCP effectiveness 
trials may yield null findings: Effectiveness can only be assessed if SCPs are used in 
practice. This suggests that cancer care quality improvement organizations’ efforts should be 
targeted at supporting programs in implementing quality improvement tools such as SCPs.
In particular, our results suggest that cancer programs may lack direction regarding how to 
comply with SCP use guidelines. The discrepancy between SCP use development and 
delivery may reflect confusion regarding how to address SCP use guidelines. Cancer care 
quality improvement organizations may promote consistent SCP use by specifying how 
adherence to guidelines will be assessed. Specifically, is developing SCPs sufficient, or must 
they also be delivered to comply with guidelines? Clearer guidelines may aid cancer 
programs in effectively implementing SCPs. In turn, effective SCP implementation will 
promote effectiveness trials’ validity. Results will inform optimal practices; ideally, optimal 
practices minimize the amount of time providers spend on ineffective practices and 
maximize survivors’ benefit.
Future research
In this study, we explored a broad range of barriers to SCP use consistency; previous studies 
have focused on lack of resources [14, 19]. Although results were not statistically 
significant, approximately one quarter of respondents reported that barriers to SCP use in 
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their cancer program included the perception that SCPs are difficult to use and that 
influential people (e.g., physician champions, managers) have not advocated for SCPs to be 
used. Future research should more closely explore these barriers to SCP use. Future research 
should also identify mechanisms underlying relationships between SCP use consistency and 
survivors’ requests for SCPs, membership in NCCCP, and geographic region. For example, 
does a survivor’s request for SCPs initiate conversations that encourage providers to 
prioritize SCP use? Are NCCCP SCP use goals particularly helpful in promoting consistent 
SCP use? Are there characteristics of regions in which SCPs are inconsistently used that 
suggest alternate approaches to promoting SCP use? For example, are electronic health 
records that can be transmitted from oncologists to PCPs particularly important in low-
density areas including parts of the Midwest?
Reliable and valid measures of SCP use consistency and its determinants must be developed. 
For example, it remains unclear whether developing SCPs and including them in health 
records is sufficient, or if SCPs must be delivered to survivors and their PCPs to qualify as 
effective SCP use. Reliable and valid measures will bring us closer to understanding 
determinants of SCP use consistency; understanding determinants of SCP use consistency 
will help to target efforts to promote SCP use consistency and, in turn, the potential for 
survivors to benefit from SCPs.
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Table 1
Survey item response options and frequencies (n = 36)
# Item Response options Frequency (%)
1 For approximately what percentage of all survivors in 
your cancer center are SCPs developed? Please check 





Don’t know 3 (8.33)
2 Approximately what percentage of SCPs is delivered to 






Don’t know 3 (8.57)
3 Approximately what percentage of SCPs is delivered to 
survivors’ primary care providers? Please circle one 





Don’t know 6 (16.67)
4 Why did/will your cancer program begin using SCPs? 
Please check all that apply.
Desire to comply with American College of Surgeons 
(ACoS) Commission on Cancer (CoC) cancer program 
2012 standards
28 (77.63)
Desire to comply with Association of Community Cancer 
program (ACCC) 2009 guidelines
7 (18.42)
Desire to comply with National Coalition for Cancer 
Survivorship (NCCS)/Lance Armstrong Foundation 
recommendations
3 (9.21)
Desire to comply with American Society for Clinical 
Oncology (ASCO) practice guidelines
16 (43.42)
Desire to comply with National Comprehensive Cancer 
Network (NCCN) guidelines
19 (53.95)
Desire to comply with National Cancer Institute (NCI) 
Community Cancer Centers Program (NCCCP) guidelines
10 (28.95)
Institute of Medicine’s (IOM) From Cancer Patient to 
Cancer Survivor raised awareness
8 (21.05)
Grant-funded SCP use project raised awareness 2 (5.26)
Colleague(s) raised awareness 8 (21.05)
Competing cancer program that uses SCPs raised 
awareness
3 (9.21)
It’s a commonly accepted practice 6 (15.79)
Belief that it may improve quality of care 27 (75.00)
Survivors requested SCPs 5 (14.47)
Other ________________________________ 4 (10.53)
5 In your opinion, what are barriers to SCP use in your 
cancer program? Please check all that apply.
Perception that SCPs are not useful. 4 (11.84)
Perception that SCPs are difficult to use. 10 (28.95)
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# Item Response options Frequency (%)
Influential people (e.g., physician champions, managers) 
have not advocated for SCPs to be used.
9 (23.68)
Influential people (e.g., physician champions, managers) 
advocating for SCPs to be used does not motivate 
providers to use SCPs.
3 (9.21)
There are not enough resources (e.g., time, staff, training, 
money) to use SCPs.
27 (76.32)
There are not enough opportunities to use SCPs. 1 (1.32)
Providers do not feel confident in using SCPs. 3 (3.95)
Other ________________________________ 8 (22.37)
6 Approximately how many new cancer patients are seen 
in your cancer program per year? Your best guess is 
fine.
1279.63a








8 Please indicate your cancer program type. Please check 
all that apply.
National Cancer Institute-designated comprehensive 
cancer program
3 (8.80)
Teaching hospital cancer program 8 (23.50)
Pediatric cancer program 3 (8.80)
Community hospital comprehensive cancer program 11 (29.40)
Community hospital cancer program 7 (20.60)
Otherc 3 (8.80)
9 Of which professional society/societies is your cancer 
program a member? Please check all that apply.
Association of Community Cancer Centers (ACCC) 15 (42.90)
American College of Surgeons (ACoS) Commission on 
Cancer (CoC)
30 (83.30)
American Society for Clinical Oncology (ASCO) Quality 
Oncology Practice Initiative (QOPI)
12 (34.30)
National Comprehensive Cancer Network (NCCN) 12 (33.30)
NCI Community Cancer Centers Program (NCCCP) 8 (22.90)
Don’t know 1 (2.78)
10 What is your current position in the cancer program? 
Please check all that apply.
Physician 2 (5.70)
Nurse practitioner 8 (22.90)
Registered nurse 14 (40.00)
Other clinical 6 (17.10)
Non-clinical administrative 5 (14.30)
a
Average number of new cancer patients per year
b
ZIP codes identified as urban or rural using Rural-Urban Commuting Areas data
c
Network cancer program, Veterans Affairs cancer program, pediatric cancer program component, hospital associate cancer program, affiliate 
hospital cancer program, integrated cancer program, freestanding cancer center program, or National Cancer Institute-designated network
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Table 2
Consistency of survivorship care plan (SCP) use (n = 36)
Variable Frequency (%)
SCPs developed for at least 75 percent of the cancer program’s survivors 5 (15.2)
SCPs delivered to at least 75 percent of survivors for whom an SCP was developed 8 (25)
SCPs delivered to at least 75 percent of survivors’ primary care providers 7 (23.3)
SCPs developed for at least 75 percent of the cancer program’s survivors AND delivered to at least 75 percent of survivors 
for whom an SCP was developed AND delivered to at least 75 percent of survivors’ primary care providers
1 (3.8)
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